Corvad as a bridge to LVAD implantation in end-stage heart disease complicated by cardiogenic shock: a three-case series - Takeaways - MDSpire

Corvad as a bridge to LVAD implantation in end-stage heart disease complicated by cardiogenic shock: a three-case series

  • By

  • Jianhao Hu

  • Wei Li

  • Chengxin Zhang

  • Yuyong Liu

  • May 25, 2026

  • 0 min

Share

  • 1

    CorVad effectively stabilized hemodynamics in three patients with advanced heart failure and cardiogenic shock prior to LVAD implantation.

  • 2

    All patients demonstrated improved mean arterial pressure, cardiac output, and reduced lactate levels after receiving CorVad support.

  • 3

    Successful elective LVAD implantation was achieved in all patients without procedural complications or in-hospital mortality.

  • 4

    Mild hemolysis indicators showed modest declines in hemoglobin and hematocrit, with slight increases in indirect bilirubin post-implantation.

  • 5

    CorVad serves as a timely hemodynamic rescue option, facilitating safe transition to durable LVAD therapy with favorable short-term outcomes.

Original Source(s)

Corvad as a bridge to LVAD implantation in end-stage heart disease complicated by cardiogenic shock: a three-case series

  • by Jianhao Hu, Wei Li, Chengxin Zhang, Yuyong Liu

  • May 25, 2026

Related Content

Transcatheter closure of PDA: how the pathway changed from classical fluoroscopy approach

Efficacy and safety of FangJiHuangQi granule in patients with heart failure: a protocol of randomized, placebo-controlled trial

Safety and efficacy of sacubitril/valsartan vs. benazepril administered as initial treatment for STEMI patients with mid-range ejection fraction: a propensity score matching analysis